Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ru Feng

Showing results (521-530 of 540) with videos related to

Pageof 54
Sort By:
Nature Plants|March 28, 2025
Horizontally acquired CSP genes contribute to wheat adaptation and improvementKai Wang, Guanghui Guo, Shenglong Bai, et al.
Journal of Medicinal Chemistry|November 19, 2019
Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address ConceptLi Xiao, Yujun Wang, Mumei Zhang, et al.
JAMA Network Open|November 30, 2021
Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical TrialNing Li, Yuan Zhu, Lu-Ying Liu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A TAD-informed aging-brain xQTL atlas of multi-modal and cell-type-resolved regulatory variationJeffrey Cifello, Ru Feng, Francis P Grenn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Chinese Medical Journal|July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional StudyJian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Blood Advances|November 24, 2020
A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative dataYe-Jun Wu, Ming Hou, Hui-Xin Liu, et al.
Signal Transduction and Targeted Therapy|June 2, 2026
Anti-asthma drug montelukast induces autistic behaviors via disrupting neuronal retinoic acid signalingZi-Jian Hao, Qiong-Hui Wu, Ya-Li Li, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
Pageof 54

Showing results (521-530 of 540) with videos related to

Sort By:
Pageof 54
Nature Plants|March 28, 2025
Horizontally acquired CSP genes contribute to wheat adaptation and improvementKai Wang, Guanghui Guo, Shenglong Bai, et al.
Journal of Medicinal Chemistry|November 19, 2019
Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address ConceptLi Xiao, Yujun Wang, Mumei Zhang, et al.
JAMA Network Open|November 30, 2021
Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical TrialNing Li, Yuan Zhu, Lu-Ying Liu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A TAD-informed aging-brain xQTL atlas of multi-modal and cell-type-resolved regulatory variationJeffrey Cifello, Ru Feng, Francis P Grenn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Chinese Medical Journal|July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional StudyJian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Blood Advances|November 24, 2020
A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative dataYe-Jun Wu, Ming Hou, Hui-Xin Liu, et al.
Signal Transduction and Targeted Therapy|June 2, 2026
Anti-asthma drug montelukast induces autistic behaviors via disrupting neuronal retinoic acid signalingZi-Jian Hao, Qiong-Hui Wu, Ya-Li Li, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
Pageof 54